<DOC>
	<DOCNO>NCT00297570</DOCNO>
	<brief_summary>The study control randomize Philadelphia-positive chronic myeloid leukemia ( Ph+ CML ) patient complete cytogenetic response one year imatinib therapy . The aim explore possible benefit addition peg-interferon ( Peg-IFN ) imatinib , term rate achievement , molecular remission , response duration .</brief_summary>
	<brief_title>Imatinib Versus Imatinib Peg-Interferon Patients With Ph+ CML Complete Cytogenetic Response After Imatinib Therapy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Ph+ CML patient complete cytogenetic response ( CCR ) 1 year imatinib therapy . Patients imatinib study Patients history intolerability interferon . Patients less CCR less one year imatinib therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>CML</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Pegylated Interferon</keyword>
	<keyword>Philadelphia Positive CML</keyword>
</DOC>